Prostatype Genomics AB announces final outcome of preferential share issue
Prostatype Genomics AB ("Prostatype Genomics" or the "Company") announces today the final outcome of the share issue with preferential rights for the Company's shareholders ("Preferential Share Issue") whose subscription period ended on 11 May 2023. The subscription summary shows that 77,226,496 shares, corresponding to approximately 56.3 percent of the Preferential Share Issue was subscribed with or without the support of subscription rights, of which 71,151,384 shares, corresponding to approximately 51.9 percent of the Preferential Share Issue, were subscribed with the support of